Surmodics, Inc. revised earnings guidance for the fiscal year 2024. For the period, the company now expects fiscal 2024 total revenue to range from $122 million to $124 million, representing a decrease of (8)% to (6)% compared to fiscal 2023. Excluding SurVeil DCB license fee revenue, Surmodics expects fiscal 2024 total revenue to range from $118 million to $120 million, representing an increase of 15% to 17% compared to fiscal 2023.

The company?s prior guidance called for fiscal 2024 total revenue of $117 to $121 million, representing a decrease of (12)% to (9)% compared to fiscal 2023, and total revenue excluding SurVeil DCB license fee revenue of $113 million to $117 million, representing an increase of 10% to 14% compared to fiscal 2023. The company now expects fiscal 2024 GAAP diluted loss per share to range from $(0.90)to $(0.70). The company?s prior guidance called for fiscal 2024 GAAP diluted loss per share to range from $(1.40) to $(1.10).